Squamous Cell Carcinoma

Back

Author

Lorraine Jennings, MBBCh, MRCPI, Fellow, Department of Dermatology, Mohs Micrographic Surgery Center, Brigham and Women's Hospital, Harvard Medical School

Nothing to disclose.

Coauthor(s)

Chrysalyne D Schmults, MD, MSCE, Assistant Professor of Dermatology, Harvard Medical School; Director, Mohs Micrographic Surgery Center, Department of Dermatology, Brigham and Women's Hospital and Dana Farber Cancer Center

Nothing to disclose.

Specialty Editor(s)

Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania

AMGEN Consulting fee Consulting; AMGEN Grant/research funds Investigator; Genentech Grant/research funds investigator; Centocor Consulting fee Consulting; Abbott Grant/research funds investigator; Abbott Consulting fee Consulting; Novartis investigator; Pfizer Grant/research funds investigator; Celgene Consulting fee DMC Chair; NIAMS and NHLBI Grant/research funds investigator

Mary Farley, MD, Dermatologic Surgeon/Mohs Surgeon, Anne Arundel Surgery Center

Nothing to disclose.

Michael J Wells, MD, Associate Professor, Department of Dermatology, Texas Tech University Health Sciences Center

Nothing to disclose.

R Stan Taylor, MD, Professor of Dermatology, University of Texas Southwestern Medical School; Director of Skin Surgery and Oncology Clinic, Department of Dermatology, University of Texas Southwestern Medical Center

Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center

Nothing to disclose.

Background

Cutaneous squamous cell carcinoma (SCC) is the second most common form of skin cancer and accounts for 20% of cutaneous malignancies.[1] Squamous cell carcinoma frequently arises on the sun-exposed skin of middle-aged and elderly individuals. Most squamous cell carcinomas are readily identified and removed in the physician's office as a minor surgical procedure. Larger and more invasive lesions may require aggressive surgical management, radiation therapy, or both. High-risk squamous cell carcinoma carries a significant risk of metastasis and, as such, requires careful evaluation and treatment. An estimated 8000 cases of nodal metastasis and 3000 deaths occur in the United States annually, almost wholly attributable to aggressive or high-risk squamous cell carcinoma.[2, 3]

General risk factors associated with the development of squamous cell carcinoma are as follows[4, 5, 6, 7, 8, 9, 10, 11] :

Pathophysiology

Squamous cell carcinoma (SCC) is a malignant tumor of epidermal keratinocytes. Some cases of squamous cell carcinoma occur de novo (ie, in the absence of a precursor lesion); however, some squamous cell carcinomas arise from sun-induced precancerous lesions known as actinic keratoses. Patients with multiple actinic keratoses are at increased risk for developing squamous cell carcinoma.[12] Squamous cell carcinoma is capable of locally infiltrative growth, spread to regional lymph nodes, and distant metastasis, most often to the lungs.

Epidemiology

Frequency

United States

Determining the true incidence of squamous cell carcinoma (SCC) is difficult because health registries exclude nonmelanoma skin cancer (including squamous cell carcinoma) from their databases because of the high number of cases and limited resources to collect data and because the rate of squamous cell carcinoma varies based on geographic locale. In 1994, the annual incidence in the United States ranged from 81-136 cases per 100,000 population for men and 26-59 cases per 100,000 population for women.[13]

Studies also confirm a dramatic increase in the incidence of cutaneous squamous cell carcinoma over the past several decades. For example, in Rochester, Minnesota, the annual age-adjusted incidence rates of squamous cell carcinoma per 100,000 women rose from 47 cases from 1984-1986 to 100 cases from 1990-1992. The corresponding rates for men increased from 126 cases to 191 cases per 100,000 population.[14]

One reason for the rising incidence of squamous cell carcinoma may be an increase in sun exposure in the general population. Some postulate that ozone depletion may be intensifying UV exposure. Other factors that may contribute to the increased incidence of squamous cell carcinoma include the advancing age of the US population, earlier and more frequent diagnosis of squamous cell carcinoma due to enhanced public awareness of skin cancer, and more frequent skin examinations by physicians.

Additionally, the number of patients on immunosuppressive therapy, used in solid organ transplantation and various rheumatologic and dermatologic conditions, is increasing. Squamous cell carcinoma formation has been associated with immunosuppressive drug therapy in solid organ transplantation patients, who have a markedly elevated risk of squamous cell carcinoma formation. Metastasis also may be more common in this group.[15]

International

Prevalence rates of squamous cell carcinoma (SCC) vary in different countries. The highest incidence occurs in Australia, where the age-adjusted incidence has been calculated to be 1332 cases per 100,000 population for men and 755 cases per 100,000 population for women. Again, this is likely due to large numbers of light-skinned people in this region who have had extensive sun exposure.[16]

Mortality/Morbidity

Most squamous cell carcinomas (SCCs) are readily treated and produce few sequelae. A subset of high-risk lesions causes most of the morbidity and the mortality associated with squamous cell carcinoma. Such lesions may cause extensive destruction of tissue, and their removal may entail substantial cosmetic deformity. The overall risk of metastasis for squamous cell carcinoma is in the range of 2-6%; however, rates as high as 47% have been reported for cases with extensive perineural invasion. Lymph node metastasis is associated with significant morbidity; however, 5-year survival rates as high as 73% have been achieved with the combination of surgical lymphadenectomy and radiation therapy.[17] Once lung metastasis occurs, the disease is currently incurable.

Race

Squamous cell carcinoma (SCC) is the second leading cause of skin cancer in whites.[1] Persons of Irish or Scottish ancestry have the highest prevalence in the United States. Squamous cell carcinoma is relatively rare in people of African and Asian descent, although it is the most common form of skin cancer in these groups. Squamous cell carcinoma in blacks carries a higher mortality rate, perhaps due to delayed diagnosis because tumors are more likely to occur in sun-protected areas, including the scalp and sites of previous injury and scarring.[18]

Sex

Squamous cell carcinoma (SCC) occurs in men 2-3 times more frequently than it does in women, most likely as a result of greater cumulative lifetime UV exposure.

Age

The typical age at presentation for squamous cell carcinoma (SCC) is approximately 70 years; however, this varies widely, and, in certain high-risk groups (eg, organ transplant recipients, patients with epidermolysis bullosa), squamous cell carcinoma often manifests at a much younger age.

History

A detailed patient history often reveals the presence of one or more risk factors for squamous cell carcinoma (SCC) (see general risk factors in Background). Most squamous cell carcinomas are discovered by patients and are brought to a physician's attention by the patient or a relative. The typical squamous cell carcinoma manifests as a new or enlarging lesion that concerns the patient. Squamous cell carcinoma is typically a slow-growing malignancy, but some lesions enlarge rapidly. Although most squamous cell carcinoma patients are asymptomatic, symptoms such as bleeding, weeping, pain, or tenderness may be noted, especially with larger tumors. Numbness, tingling, or muscle weakness may reflect underlying perineural involvement, and this history finding is important to elicit because it adversely impacts prognosis.[19]

Actinically derived squamous cell carcinoma

The most common type of squamous cell carcinoma is the sun-induced type. As such, a history of long-term sun exposure dating back to childhood is frequently elicited. Many patients report having experienced multiple blistering sunburns during their lifetime, while others may have used indoor tanning beds or received UV light therapy (eg, psoralen plus UVA [PUVA] for psoriasis). Patients may have been treated in the past for sun-induced lesions such as actinic keratoses, basal cell carcinoma, melanoma, or squamous cell carcinoma.

Immune suppression

Patients should always be questioned about possible sources of immunosuppression. A history of solid-organ transplantation, hematologic malignancy (particularly chronic lymphocytic leukemia), HIV infection or AIDS, or long-term use of immunosuppressive medications (eg, as treatment for an autoimmune condition) may be elicited.

Marjolin ulcer

This eponym most frequently refers to a squamous cell carcinoma that arises from chronically scarred or inflamed skin; however, malignant transformation to a basal cell carcinoma, melanoma, or sarcoma may also occur.[20] Patients may report a change in the skin (eg, induration, elevation, ulceration, weeping) at the site of a preexisting scar or ulcer. The average latency period is 35 years[21] ; therefore, the diagnosis requires a high index of clinical suspicion. Marjolin ulcers are associated with a high rate of metastasis, estimated at 30%,[22, 23] and a mortality rate of 33%.[24]

HPV-associated squamous cell carcinoma

Virally induced squamous cell carcinoma most commonly manifests as a new or enlarging warty growth on the penis, vulva, perianal area, or periungual region. Patients often present with a history of "warts" that have been refractory to various treatment modalities in the past. A history of previously documented genital HPV infection may be elicited.

Physical

Squamous cell carcinoma (SCC) may manifest as a variety of primary morphologies, with or without associated symptoms. Note the following:

Squamous cell carcinoma in situ

Squamous cell carcinoma in situ is defined histologically by atypia involving the full thickness of the epidermis but without invasion into the dermis. Clinically, lesions of squamous cell carcinoma in situ range from a scaly pink patch to a thin keratotic papule or plaque similar to an actinic keratosis. Bowen disease is a subtype of squamous cell carcinoma in situ characterized by a sharply demarcated pink plaque arising on non–sun-exposed skin. Erythroplasia of Queyrat refers to Bowen disease of the glans penis, which manifests as one or more velvety red plaques.

Note the images below.


View Image

Sun-induced squamous cell carcinoma on the face with overlying hyperkeratosis, a common feature.


View Image

Squamous cell carcinoma of the penis. Courtesy of Hon Pak, MD.

Typical squamous cell carcinoma

The characteristic invasive squamous cell carcinoma is a raised, firm, pink-to-flesh–colored keratotic papule or plaque arising on sun-exposed skin. Approximately 70% of all squamous cell carcinomas occur on the head and neck, with an additional 15% found on the upper extremities. Surface changes may include scaling, ulceration, crusting, or the presence of a cutaneous horn. Less commonly, squamous cell carcinoma may manifest as a pink cutaneous nodule without overlying surface changes. The absence of surface changes should raise suspicion of a metastatic focus from another skin or nonskin primary site or a different and potentially more lethal tumor such as Merkel cell carcinoma. A background of severely sun-damaged skin, including solar elastosis, mottled dyspigmentation, telangiectasia, and multiple actinic keratoses, is often noted.

Note the images below.


View Image

Sun-induced squamous cell carcinoma on the face with superficial erosion.


View Image

Squamous cell carcinoma. Courtesy of Hon Pak, MD.

Periungual squamous cell carcinoma

Periungual squamous cell carcinoma typically mimics a verruca and is frequently misdiagnosed for years as a wart prior to biopsy. Less commonly, lesions may resemble chronic paronychia with swelling, erythema, and tenderness of the nail fold; onychodystrophy also may be noted. Periungual squamous cell carcinomas are frequently associated with HPV.[25]

Marjolin ulcer

This subtype of squamous cell carcinoma appears as a new area of induration, elevation, or ulceration at the site of a preexisting scar or ulcer. Patients with this form of squamous cell carcinoma can have a poor prognosis. The diagnosis of Marjolin ulcer should be considered in any ulcer that fails to heal with standard therapy.

Perioral squamous cell carcinoma

Squamous cell carcinoma of the lip usually arises on the vermillion border of the lower lip. It is sometimes predated by a precursor lesion, actinic cheilitis, which manifests as xerosis, fissuring, atrophy, and dyspigmentation. Actinic cheilitis is analogous to actinic keratosis of the skin. Squamous cell carcinoma on the lip manifests as a new papule, erosion, or focus of erythema/induration. Intraoral squamous cell carcinoma typically manifests as a white plaque (leukoplakia) with or without reddish reticulation (erythroplakia). Common locations include the anterior floor of the mouth, the lateral tongue, and the buccal vestibule.

Anogenital squamous cell carcinoma

Squamous cell carcinoma in the anogenital region may manifest as a moist, red plaque on the glans penis; indurated or ulcerated lesions may be seen on the vulva, external anus, or scrotum. Associated symptoms include pain, pruritus, and intermittent bleeding. These squamous cell carcinomas are also associated with HPV infection.

Verrucous carcinoma

Verrucous carcinoma is a subtype of squamous cell carcinoma that can be locally destructive but rarely metastasizes. Lesions appear as exophytic, fungating, verrucous nodules or plaques, which may be described as cauliflowerlike. Verrucous carcinoma is further subdivided based on its location in the anogenital region (Buschke-Löwenstein tumor), the oral cavity (oral florid papillomatosis), and the plantar foot (epithelioma cuniculatum).

Lymphadenopathy

With any invasive (not in situ) squamous cell carcinoma, regional lymph nodes should be examined. Lymph node enlargement must be further evaluated by fine-needle aspiration (FNA) or nodal biopsy.

Causes

The primary cause of most squamous cell carcinoma (SCC) is cumulative lifetime sun exposure. The frequency of squamous cell carcinoma is increased at lower latitudes, correlating with an increased intensity of ambient light. Other causes of squamous cell carcinoma are discussed below.

UV sunlight exposure

The component of sunlight believed to be most important in cutaneous carcinogenesis is UVB (290-320 nm), which is both an initiator and a promoter of carcinogenesis. In animal models, UV-induced photocarcinogenesis appears to involve the UVB and UVA-2 spectral ranges.[26]

UVB-induced photocarcinogenesis appears to work by suppressing the immune system in several ways. The UVB spectrum inhibits antigen presentation, induces the release of immunosuppressive cytokines, and elicits DNA damage, specifically the generation of pyrimidine dimers in keratinocyte DNA that is a molecular trigger of UV-mediated immunosuppression.[27]

Inactivation of the tumor suppressor gene TP53 occurs in up to 90% of all cutaneous squamous cell carcinoma lesions.[28] Other tumor suppressor genes found to be mutated in squamous cell carcinoma include P16 (INK4a) and P14 (ARF).[29]

Therapeutic UV exposure

UV light treatments used for psoriasis (and other recalcitrant dermatoses) also predispose to the development of squamous cell carcinoma. PUVA is particularly phototoxic and mutations in both TP53 and the oncogene Ha-Ras are present in a large proportion of PUVA-associated squamous cell carcinoma.[30] In addition to being mutagenic, UVA in conjunction with UVB is a potent suppressor of the cutaneous immune system, which likely contributes to its role in cutaneous carcinogenesis.

Fair complexion

Individuals with skin types I and II account for most of the patients who develop squamous cell carcinoma; patients with oculocutaneous albinism are also at risk, and squamous cell carcinomas account for the most common type of cutaneous malignancy in this group. Such individuals lack natural protection from UV-induced carcinogenesis, owing to reduced levels of the photoprotective pigment, melanin.[31]

Ionizing radiation

Therapeutic ionizing radiation is typically associated with the later development of basal cell carcinomas, but the risk of developing squamous cell carcinomas is also increased.[32] Most patients with radiation-induced tumors have a remote history of x-ray therapy for acne vulgaris, although patients developing squamous cell carcinoma in radiation ports for Hodgkin disease or thyroid cancer treatment is not uncommon.

Chemical carcinogens

Exposure to arsenic is a well-established cause of cutaneous squamous cell carcinoma and internal cancers.[6] Today, the main source of arsenic is contaminated well water, although arsenic may also be found in traditional Chinese medicines. Other carcinogens associated with squamous cell carcinoma include polycyclic aromatic hydrocarbons such as tar, soot, and pitch.

DNA repair failure

Healthy human skin is constantly repairing UV-induced damage through DNA repair mechanisms. Patients with xeroderma pigmentosum have a deficiency in an enzyme essential for normal DNA repair and are thus prone to the development of innumerable squamous cell carcinomas, and, less commonly, other cutaneous tumors.[33]

Iatrogenic immunosuppression

The use of immunosuppressive medications to prevent rejection in organ transplant recipients is associated with a 65- to 250-fold increased risk of developing squamous cell carcinoma compared with the general population.[34]

The primary risk factor in these patients is cumulative lifetime UV exposure in combination with having Fitzpatrick skin type I or II. This risk also increases with the number of years post-transplantation, presumably because of the cumulative effects of prolonged immunosuppressive therapy.

The greatest risk occurs in heart transplant patients, with diminishing risk seen in recipients of kidney and liver transplants, which correlates with the degree of immunosuppression (ie, number and/or dosage of medications) typically required to prevent rejection in these patient populations.

Pretransplantation end-organ disease may also impact the development of post-transplant squamous cell carcinoma. For example, among renal transplant recipients, the highest prevalence of skin cancer was observed in patients with polycystic kidney disease, while the lowest incidence was seen in those with diabetic nephropathy. Similarly, cholestatic liver disease was associated with a greater post-transplantation risk of skin cancer compared with other causes of liver failure.

Noniatrogenic immunosuppression

In addition to iatrogenic immunosuppression, defects in cell-mediated immunity related to lymphoproliferative disorders (eg, chronic lymphocytic leukemia) predispose to the development of aggressive squamous cell carcinoma. The specific mechanisms by which immunosuppression leads to squamous cell carcinoma development are poorly understood, but diminished immunosurveillance is thought to be critical. CD8+ T cells specific for the tumor suppressor gene TP53 have been observed in patients with squamous cell carcinoma, suggesting that a functional immune system may target keratinocytes expressing mutated TP53.[35] Suppression of the immune system would presumably abrogate this response and might be expected to facilitate the development of squamous cell carcinoma.

Human papillomavirus

Infection with specific subtypes of HPV is believed to play a role in the development of anogenital and periungual squamous cell carcinoma. Attempts to definitively link squamous cell carcinoma to HPV have yielded contradictory results, as most squamous cell carcinomas tumors outside of anogenital and periungual sites do not contain HPV. The International Agency for Research on Cancer (IARC; Lyon, France) has determined that current evidence only supports HPV types 5 and 8 as possible carcinogens.[36] However, HPV types 6 and 11 have been associated with Buschke-Löwenstein tumors, whereas HPV type 16 has been frequently identified in both genital and periungual squamous cell carcinoma, suggesting the possibility of genital-digital spread.[37, 38] HPV types 5 and 8 have been associated with cutaneous squamous cell carcinoma in the setting of epidermodysplasia verruciformis and some solid organ transplant patients.[39]

Chronic inflammation

Chronic inflammation, irrespective of the underlying etiology, may lead to the development of squamous cell carcinoma. Both noninfectious inflammatory diseases and chronic infections have been associated with squamous cell carcinoma.

Likewise, the Marjolin ulcer variant of squamous cell carcinoma may develop in patients with a chronic scarring condition such as dystrophic epidermolysis bullosa. In fact, the leading cause of death in patients with dystrophic epidermolysis bullosa is metastatic cutaneous squamous cell carcinoma,[10] with an 80% mortality rate within 5 years of diagnosis of squamous cell carcinoma[40] and with two thirds of patients dying from metastatic disease.[41] More recently, evidence suggests that patients with junctional epidermolysis bullosa may also be at increased risk for developing squamous cell carcinoma.[42] The underlying pathogenesis of such lesions is not understood, but mutations in the TP53 and P16 tumor suppressor genes have been described in dystrophic epidermolysis bullosa–associated squamous cell carcinoma.[43]

Conditions that predispose to the development of squamous cell carcinoma

Chronic inflammatory and scarring conditions are as follows:

Chronic infections are as follows:

Genetic syndromes and dermatoses are as follows:

Imaging Studies

Imaging is not routinely indicated for diagnosing cutaneous (SCC). However, radiologic imaging should be obtained in patients with regional lymphadenopathy and/or neurologic symptoms suggestive of perineural involvement, for nodal staging, and for preoperative planning in patients in whom deep or extensive tissue involvement is suspected. CT scanning, MRI, ultrasonography, or positron-emission tomography (PET) scanning may be used depending on the specific question being addressed, although the selection of one modality over another is often based on clinician and institutional preference. Currently, no formal guidelines have been developed regarding the use of radiologic imaging in cutaneous squamous cell carcinoma.

Disease staging workup in high-risk squamous cell carcinoma

Physical examination of lymph nodes

In all squamous cell carcinoma patients, the draining nodal basins should be palpated. If nodes are palpable, a biopsy should be performed using fine-needle aspiration (FNA) or excision. If lymph nodes are clinically negative but the tumor meets high-risk criteria, little data are available to guide what should be done next. Subsequently, management currently varies with regard to further staging.[44] See "High-risk squamous cell carcinoma" in Prognosis.

Radiologic staging

Only a few studies have reported on the utility of radiologic imaging in cutaneous squamous cell carcinoma. One study of MRI and CT scanning in patients with histologically proven perineurally invasive squamous cell carcinoma showed that only 20% of asymptomatic patients have positive findings discovered from imaging studies. Thus, CT scanning and MRI appear to be poor in detecting asymptomatic nerve involvement. However, positive imaging findings did correlate with worse outcomes. The 5-year survival rate was 50% if CT scanning or MRI findings were positive, versus 86% if they were negative.[45]

Two studies reported on radiologic imaging for detecting subclinical nodal metastasis.[46] The first, a study of vulvar squamous cell carcinoma, indicated that ultrasonography followed by FNA for suspicious nodes was superior to CT scanning in staging subclinical nodal metastasis, with ultrasound-guided FNA demonstrating 80% sensitivity and 100% specificity. The second is a small study of PET scanning in 9 patients with high-risk squamous cell carcinoma. PET scanning detected subclinical nodal metastasis in 3 of 9 patients.[47] Thus, PET scanning and ultrasound-guided FNA may be capable of detecting many cases of subclinical nodal metastasis.

Sentinel lymph node biopsy

A review of the 85 reported cases of sentinel lymph node biopsy (SLNB) in high-risk, nonanogenital cutaneous squamous cell carcinoma showed that 21% of cases were positive based on SLNB findings. This indicates that SLNB likely can detect many cases of subclinical nodal metastasis. How the sensitivity of SLNB compares with that of PET scanning or ultrasound-guided FNA and whether detection of subclinical nodal metastasis impacts survival are unknown.[48] However, because the 5-year survival rate of patients with nodal metastasis is as high as 73% with aggressive treatment,[17] early detection of nodal metastasis may prove more beneficial in squamous cell carcinoma than in melanoma.

Summary

Little data are available to guide decisions about staging of nodal basins in high-risk squamous cell carcinoma. However, PET scanning, ultrasound-guided FNA, and SLNB all appear to offer a good chance of detecting subclinical nodal metastasis with low morbidity. Thus, nodal staging may be considered in patients with high-risk squamous cell carcinoma. Development of prognostic models that better predict the risk of nodal metastasis will allow for more rational decisions about which patients should undergo nodal staging.

Procedures

Skin biopsy

Although the diagnosis of squamous cell carcinoma (SCC) is often strongly suggested based on clinical findings, a skin biopsy is required for definitive diagnosis. A shave biopsy, punch biopsy, incisional biopsy, or excisional biopsy may be used. The biopsy is routinely performed in the physician's office after the patient is given a local anesthetic.

All skin biopsy samples obtained to diagnose squamous cell carcinoma must reach at least the depth of the mid dermis to allow for a determination of the presence or absence of invasive disease. For high-risk lesions, a larger sample may be helpful to assess for perineural invasion and other histologic features that confer a greater risk of metastasis. Given recent information about depth being an important prognostic factor (analogous to melanoma), a large punch biopsy through the center of the lesion or excisional biopsy may be best, particularly in high-risk lesions or immunosuppressed patients.[3]

Pathologic analyses may be completed by a dermatologist or a general pathologist, but they are preferably completed by a dermatopathologist with extensive experience in squamous cell carcinoma.

Patients with regional lymphadenopathy identified by clinical examination or imaging studies should undergo a lymph node biopsy or FNA for histologic evaluation. SLNB has been used to identify micrometastasis in patients with high-risk squamous cell carcinoma and clinically negative nodes, with 21% positivity.[48] While SLNB appears to be able to detect most subclinical metastasis, whether early detection of lymph node metastasis leads to enhanced survival in squamous cell carcinoma is unknown, because controlled studies have not been conducted. Complete lymphadenectomy of the draining nodal basin has also been suggested for high-risk tumors with an estimated metastatic risk of 20% or greater. However, because prognostic models do not exist, knowing precisely which patients fall into this category is difficult. Thus, when it is feasible, SLNB offers a low-morbidity approach to accurately staging high-risk squamous cell carcinoma.

Histologic Findings

The biopsy report for squamous cell carcinoma (SCC) often carries prognostic implications. Recognizing the implications of the various histologic subtypes of squamous cell carcinoma is important, and the astute clinician uses his or her understanding of histopathology to advantage in planning the appropriate therapeutic intervention.

Squamous cell carcinoma in situ is characterized by an intraepidermal proliferation of atypical keratinocytes. Hyperkeratosis, acanthosis, and confluent parakeratosis are seen within the epidermis, and the keratinocytes lie in complete disorder, resulting in the classic "windblown" appearance. Cellular atypia, including pleomorphism, hyperchromatic nuclei, and mitoses, is prominent. Atypical keratinocytes may be found in the basal layer and often extend deeply down hair follicles, but they do not invade the dermis.

The main feature that distinguishes invasive squamous cell carcinoma from squamous cell carcinoma in situ is invasion of malignant keratinocytes through the basement membrane and into the dermis. Keratinization results in the production of squamous eddies or keratin pearls. The neoplastic cells may demonstrate varying degrees of squamous differentiation and atypia. If the tumor is poorly differentiated, this fact is typically reported by the dermatopathologist because the degree of differentiation has prognostic implications (ie, poorly differentiated tumors have been associated with a higher risk of metastasis).

Several variants of squamous cell carcinoma can be distinguished by clinical and/or histologic criteria. In some cases, these tumors may be difficult to distinguish from other malignancies based on routine histology findings alone. Therefore, immunohistochemical staining with antibodies to cytokeratins and epithelial membrane antigen is often used to confirm the epithelial (ie, keratinocyte) origin of the tumor. The salient features of keratoacanthoma, spindle cell squamous cell carcinoma, acantholytic (adenoid) squamous cell carcinoma, and verrucous carcinoma are highlighted in the following table.

Histologic and Clinical Features of Squamous Cell Carcinoma Variants


View Table

See Table

Staging

Squamous cell carcinoma (SCC) is staged according to American Joint Committee on Cancer (AJCC) guidelines, which use the tumor, node, metastasis (TNM) classification system.[49] This staging system has been updated to incorporate information about tumor factors that impact prognosis. Cutaneous squamous cell carcinoma of the eyelid is excluded from the updated system.

The previous staging system had classified tumor stage based solely on tumor diameter and invasion of deep structures (cartilage, muscle, or bone). Along with tumor diameter, the new system incorporates the following high-risk features:

T1 tumors are those 2 cm or less in diameter and with 0 or 1 high-risk features. T2 tumors are those with diameters exceeding 2 cm or with 2 or more high-risk features. T3 tumors are those involving facial bones (maxilla, mandible, orbit, or temporal). T4 tumors are those with other bone involvement or with perineural invasion involving the skull base.

The new TNM staging system has also revised nodal staging. Previously, the system had only had a single N1 level to signify nodal involvement. The new system has 5 levels. The decision to stage patients according to extent of nodal disease was based on significant findings of several studies, both prospective and retrospective, showing that the number and size of lymph node involvement correlated with patient prognosis.[50, 51, 52, 53, 54]

In the new staging system, N1 disease involves a single ipsilateral node 3 cm or smaller in its largest dimension. N2a disease includes cases with a single ipsilateral node greater than 3 cm but less than or equal to 6 cm. N2b refers to those with multiple ipsilateral nodes smaller than or equal to 6 cm. N2c includes cases of bilateral or contralateral involvement less than or equal to 6 cm. N3 disease is reserved for cases with any involved node greater than 6 cm.

In early 2010, Milross et al proposed an alternative nodal staging system (the N1S3), which also stages cutaneous squamous cell carcinoma patients based on the number (single or multiple) and size (< or > 3 cm) of lymph nodes involved, but also incorporates the parotid as one of the regional levels. Stage I disease refers to those with a single lymph node measuring less than or equal to 3 cm. Stage II includes cases with a single lymph node greater than 3 cm or multiple lymph nodes less than or equal to 3 cm, while stage III is any patient with multiple lymph nodes greater than 3 cm.[55] This system was found to have a significant predictive capacity for locoregional control (P < .0001), disease-specific survival (P < .0001), and overall survival (P < .0001) in a group of 215 patients and was reproduced on external validation in a cohort of 250 patients.

Distant metastases are staged according to the presence (M1) or absence (M0) of metastases in distant organs or sites outside of regional lymph nodes. This remains unchanged from the previous TNM staging system

Stage 0 is equivalent with in situ disease. Disease stages I and II include patients with T1 and T2 tumors, respectively who have no nodal or distant metastasis (N0, M0). Stage III disease includes T3 cases without nodal involvement (N0) or cases with N1 involvement. Stage IV includes those with T4 disease, or N2 or N3 disease, or distant metastasis (M1).

Medical Care

Nonsurgical options for the treatment of cutaneous squamous cell carcinoma (SCC) include topical chemotherapy, topical immune response modifiers, photodynamic therapy (PDT), radiotherapy, and systemic chemotherapy. The use of topical therapy and PDT is generally limited to premalignant (ie, actinic keratoses) and in situ lesions. Radiation therapy is a primary treatment option for patients in whom surgery is not feasible and is an adjuvant therapy for those with metastatic or high-risk cutaneous squamous cell carcinoma. In current practice, systemic chemotherapy is used exclusively for patients with metastatic disease. However, newer, more targeted drugs, such as epidermal growth factor receptor (EGFR) antagonists (eg, cetuximab), have favorable adverse effect profiles and await trails to determine if they are beneficial in high-risk squamous cell carcinoma.

Topical chemotherapy

Topical formulations of 5-fluorouracil (5-FU) are available for the treatment of actinic keratoses and superficial basal cell carcinomas. Successful treatment of in situ squamous cell carcinoma has also been reported.[56] Invasive squamous cell carcinoma should not be treated with topical chemotherapy. An oral form of a 5-FU prodrug (capecitabine), which is approved by the US Food and Drug Administration (FDA) for other forms of cancer, may be considered in patients with diffuse in situ squamous cell carcinoma over large skin areas, on which topical 5-FU is difficult to apply. However, studies of efficacy have not yet been performed.

Topical immune response modifiers

Imiquimod is an imidazoquinoline that enhances cell-mediated immune responses via the induction of proinflammatory cytokines. It is approved by the FDA for the treatment of genital warts (ie, condylomata acuminata), actinic keratoses, and superficial basal cell carcinoma. Imiquimod cream has also shown effectiveness in the treatment of Bowen disease as monotherapy and in combination with topical 5-FU. However, systemic flulike symptoms and other adverse effects can occur when applied to large surface areas; therefore, using this agent in patients with diffuse in situ squamous cell carcinoma is difficult.[57, 58]

Photodynamic therapy

Treatment with PDT involves the application of a photosensitizer (given topically or systemically) followed by exposure to a light source. The resulting photochemical reaction causes inflammation and destruction of the targeted lesion(s). PDT is used primarily to treat large numbers of actinic keratoses in a single session. Squamous cell carcinoma in situ is also amenable to PDT, although a wide range of recurrence rates (0-52%) have been reported. A study of organ transplant recipients with multiple actinic keratoses and field actinic damage showed PDT to be superior to topical 5-FU.[59] A 2009 noncomparative study showed repeated cycles of PDT to be associated with significant reduction in squamous cell carcinoma formation in organ transplant recipients.[60] At this time, PDT is not recommended for treatment of invasive squamous cell carcinoma due to poor long-term cure rates.[61]

Radiation therapy

Primary radiation therapy as a treatment option for squamous cell carcinoma offers the potential advantage of avoiding the deformity and trauma of a surgical procedure. Cure rates for T1 lesions range from 85-95%. However, a number of disadvantages are associated with radiation therapy. For example, radiation therapy is expensive and requires a significant time commitment because treatments are usually given 3-5 times per week for 4-8 weeks. Most patients experience significant irritation at the radiation site, and they frequently develop erythema, erosions, alopecia, and pain, which may require narcotic-level analgesia. Although the initial cosmetic result following radiation is usually good, the long-term outcome is often poor, owing to the development of cutaneous atrophy, dyspigmentation, and telangiectasia in the radiation field. Patients treated with radiation also have a slightly increased risk of developing cutaneous carcinoma (most commonly squamous cell carcinoma) or sarcoma later in life.

Radiation therapy does not involve histologic margin control and has a lower cure rate compared with surgery. For these reasons, as well as those discussed in the preceding paragraph, radiation as a primary therapy is usually confined to a small subset of tumors in which the cosmetic or functional outcome would be superior to that of surgery[62] or in elderly patients with inoperable squamous cell carcinoma.

In contrast, radiation is routinely used as an adjunct to surgical treatment in cases of nodal metastasis, and the reported 5-year cure rate is 73% for combined surgical and radiation therapy to involved nodal basins.[17] Squamous cell carcinomas with advanced perineural invasion have an elevated risk of recurrence, even when surgical margins are thought to be clear.[44, 48, 63] Thus, adjuvant radiation may be considered, particularly in cases involving larger nerves, although its utility has yet to be proven. A systematic review analyzing all reports related to outcomes of high-risk squamous cell carcinoma treated with surgical monotherapy compared with those treated with surgery plus adjuvant radiation[64] was unable to show an advantage of adjuvant radiation in the treatment of squamous cell carcinoma with perineural invasion. However, the available studies were uncontrolled for tumor stage and more advanced tumors with a worse baseline prognosis likely received radiation.

In summary, the additional benefit of adjuvant radiotherapy is uncertain, especially when clear surgical margins are obtained. However, it may be considered in patients with multiple high-risk factors, those with significant nerve involvement (particularly named nerves or nerves >0.1 mm in diameter), those with uncertain surgical margins (eg, poorly differentiated, infiltrative, or multiply-recurrent tumors), or as salvage therapy for in-transit metastasis or other tumors which cannot be cleared surgically. A lower threshold for adjuvant radiation should be used in immunocompromised patients with high-risk squamous cell carcinoma.[64]

Systemic chemotherapy

A variety of different chemotherapeutic agents have been used to treat metastatic cutaneous squamous cell carcinoma. Many of the current protocols have been adapted from those used to treat metastatic head and neck squamous cell carcinoma.

Cisplatin-based combination chemotherapy with 5-FU, methotrexate, bleomycin, and doxorubicin have all been used to treat advanced squamous cell carcinoma with variable outcomes.

The oral 5-FU prodrug, capecitabine (Xeloda), has been designed to be metabolized to 5-FU selectively within tumor tissues, thus producing less systemic toxicity. Either used alone, or in combination with interferon alfa, it has shown some efficacy in the treatment of advanced cutaneous squamous cell carcinoma.[65]

More recently, cetuximab, an EGFR inhibitor, has had reported as successful in several case reports.[66, 67, 68] In the head and neck literature, phase I and II trials of capecitabine, used with cisplatin or paclitaxel[69, 70] or in combination with radiation therapy[71] also showed favorable outcomes. EGFR inhibitors are well tolerated with relatively low risks, so they may be considered in cases not amenable to surgery or radiation or as an adjuvant in cases considered to have a high risk of death.

Reduction in immunosuppression

In organ transplant recipients, a reduction in the magnitude of immunosuppression may be an effective adjuvant therapeutic strategy in the treatment of aggressive squamous cell carcinoma. Because a decrease in immunosuppression may increase the risk for rejection of the transplanted organ, this strategy should only be considered in selected high-risk patients and under the careful management of the transplantation physician, who must closely monitor the patient for signs and symptoms of organ rejection.[72]

Newer immunosuppressive agents (eg, sirolimus) are associated with a lower incidence of squamous cell carcinoma when compared with more traditional agents (eg, calcineurin inhibitors), without compromise in graft function.[73, 74] Patients on sirolimus also produce thinner, less vascularized tumors,[75] likely due to the drug’s antiangiogenic and antitumor properties. In a study of 182 organ transplant recipients, the mean cumulative doses of prednisone, cyclosporine, azathioprine, and mycophenolate were significantly higher in those with skin cancer. Conversely, the cumulative doses of sirolimus and tacrolimus were significantly lower in those with skin cancer, suggesting that these drugs may be protective.

Surgical Care

Most squamous cell carcinomas (SCCs) are readily treated in the physician's office by surgical or destructive methods, with a high expectation of cure. The treatment of squamous cell carcinoma must take into account multiple patient- and lesion-specific factors. The standard modalities available for the treatment of localized (primary) invasive squamous cell carcinoma are described below. Because squamous cell carcinoma is a lesion that can recur, metastasize, and cause death, and, because recurrent squamous cell carcinoma carries a worse prognosis, every opportunity should be taken to effect complete tumor extirpation at first presentation.

Cryotherapy

Cryotherapy with liquid nitrogen is a safe and low-cost procedure for the ablation of selected in situ squamous cell carcinomas. The 5-year cure rate for squamous cell carcinoma can be 95% or greater with proper tumor selection and technique. In the United States, cryosurgery is routinely used for in situ disease and actinic keratoses. It is not often used for invasive squamous cell carcinoma because deeper portions of the tumor may not be eradicated by this technique and because the development of scar tissue at the site of cryotherapy might obscure a recurrence. The risks associated with cryotherapy include transient pain, edema, and blistering. Hypopigmentation and alopecia are also common and may be permanent, so treatment of hair-bearing areas and in darkly pigmented individuals is generally not recommended.[76]

Electrodesiccation and curettage

Electrodesiccation and curettage (ED&C) is a simple technique that can be used to treat low-risk squamous cell carcinoma on the trunk and extremities. The tumor indications are similar to those of cryotherapy. In addition, ED&C can be used to treat superficially invasive squamous cell carcinomas without high-risk characteristics. However, the thick scars that often occur after ED&C can delay the diagnosis of cancer recurrence. Subsequently, ED&C should be used with caution in invasive squamous cell carcinoma. It is not appropriate for certain anatomic locations (ie, eyelids, genitalia, lips, ears).

The technique is based on the delineation of tumor margins with a curette because tumor tissue is generally more friable than the surrounding normal tissue. ED&C is known to be very technique dependent, and cure rates improve with a practitioner's experience. The main disadvantage of ED&C is a lack of histologic margin control, and most dermatologic surgeons believe the actual long-term cure rate for invasive squamous cell carcinoma is much lower than that quoted in the literature. Tumor recurrence may result from failure of ED&C treatment to eradicate atypical cells residing deep in the hair follicles or in the dermis. Nonetheless, the procedure is fast, minimally invasive, well tolerated, and effective for properly selected lesions.

Excision with conventional margins

Standard excision with conventional permanent (ie, paraffin-embedded) tissue sections is an excellent, highly effective, and well-tolerated therapy for primary squamous cell carcinomas that lack high-risk features and are located in areas where tissue sparing is not critical. Cure rates following simple excision of well-defined T1 lesions may be as high as 95-99%. The generally accepted 5-year cure rate for primary squamous cell carcinoma treated with standard excision is 92%; this rate drops to 77% for recurrent squamous cell carcinoma.

A 4-mm margin of healthy tissue is recommended for lower-risk lesions (< 2 cm, well-differentiated, without subcutaneous fat invasion) on the trunk and extremities. For lesions larger than 2 cm, invasive to fat, and in high-risk locations (ie, central face, ears, scalp, genitalia, hands, feet), a 6-mm margin of healthy tissue is recommended. Given the cosmetic and functional impact of these wider margins, tumors in this latter category are often removed via Mohs surgery (see below) to achieve high cure rates while sparing normal tissue. The depth of an excision should always include a portion of the subcutaneous fat.

One pitfall of standard excision is that histologic margins can be reported to be negative when they are, in fact, positive (false negative) because the traditional bread-loaf method of tissue sectioning typically results in evaluation of less than 1% of the specimen’s margins. More commonly, a greater amount of healthy tissue is removed than is necessary for complete tumor extirpation. Therefore, simple excision is most valuable in the treatment of small primary squamous cell carcinomas on the trunk, extremities, or neck, where tissue sparing is less essential.[77]

Mohs micrographic surgery

Mohs micrographic surgery (MMS) is a specialized technique for removing many forms of skin cancer, including squamous cell carcinoma. Because of its many advantages, MMS is the procedure of choice for squamous cell carcinoma in which tissue preservation is needed, for ill-defined squamous cell carcinoma, recurrent tumors, and for high-risk squamous cell carcinoma. The main advantage of MMS over simple excision is the ability to histologically examine nearly 100% of the surgical margins (as compared with < 1% of the margin visualized via standard histologic sectioning) and to carefully map residual foci of invasive carcinoma. This residual tumor is removed in a step-wise fashion until clear margins are obtained.

MMS provides the best available cure rates (94-99%) for squamous cell carcinoma and has been of particular value in curing squamous cell carcinoma associated with perineural invasion. In a comprehensive historical review, Rowe et al[78] noted that local recurrences are less frequent when squamous cell carcinoma is treated with MMS compared with all non-Mohs modalities. This local recurrence rate differential in favor of MMS was observed in primary squamous cell carcinoma of the skin and lip (3.1% vs 10.9%), for locally recurrent squamous cell carcinoma (10% vs 23.3%), for poorly differentiated squamous cell carcinoma (32.6% vs 53.6%), and for squamous cell carcinoma with perineural involvement (0% vs 47%).

MMS offers the added benefit of preserving healthy tissue, thus facilitating reconstruction and optimizing cosmetic and functional outcomes. It is performed in an outpatient setting with local anesthesia and is therefore a safe and cost-effective procedure[79, 80] , and MMS is less expensive than surgical excision with anesthesia in a hospital setting.[79, 80]

As a result of the fellowship training programs in Mohs surgery overseen by the American College of Mohs Surgery and the new Accreditation Council for Graduate Medical Education (ACGME)–accredited Procedural Dermatology Fellowship programs, MMS has become widely available throughout the United States.[81, 82]

Care of patients with diffuse actinic keratosis and in situ squamous cell carcinoma

Many patients with a history of extensive sun exposure and light skin develop epidermal atypia in the form of actinic keratosis and in situ squamous cell carcinoma over large areas of their skin. Most of these patients also develop multiple invasive squamous cell carcinomas. The management of such patients is highly labor intensive and involves the following steps:

Treatment of patients with high-risk tumors

Management of primary tumors

See "High-risk squamous cell carcinoma" in Prognosis. The use of ED&C in the treatment of high-risk squamous cell carcinoma, particularly in immunocompromised individuals, is best avoided, because histologic margin status cannot be evaluated. Clear margins must be obtained for optimal outcomes.

Ensuring clear surgical margins wherever possible is highly recommended. A systematic review of available data for high-risk squamous cell carcinoma compared cases with clear surgical margins (n = 943) versus those in which margins were not specified (n = 1506) and demonstrated statistically better outcomes in cases in which clear margins were documented, with risks of local recurrence, regional metastasis, distant metastasis, and disease-specific death of 5%, 5%, 1%, and 1%, respectively, in clear-margin cases, versus 8%, 14%, 7%, and 7% in cases with undocumented margins.[64]

A prospective study identified several risk factors for incomplete excision of squamous cell carcinomas, namely, ear lesions, invasive lesions, and previously incompletely excised lesions referred for reexcision. The study also recommended more care with tumor markings, taking margins of at least 5 mm, deeper margins, and referring such lesions to centers with personnel who have more experience.[84]

No controlled comparative studies of Mohs versus excision in high-risk squamous cell carcinoma have been performed, but case series data suggest that Mohs is superior to excision for high-risk squamous cell carcinoma patients.[81]

Adjuvant therapy

No comparative studies of surgery versus surgery plus adjuvant radiotherapy for high-risk squamous cell carcinoma have been performed. With no clear evidence of benefit and the potential of significant morbidity, clinical judgment is required in deciding which patients should receive adjuvant radiation. One systematic review of available outcome data suggests that adjuvant radiation be considered in patients with uncertain or positive surgical margins or advanced nerve involvement (eg, involvement of named nerves, nerves ≥0.1 mm in diameter, or with clinical or radiologic evidence of nerve invasion).[64] Adjuvant medication may also be considered in select highest-risk cases. Options include oral 5-FU (Xeloda) and EGFR inhibitors via oncology treatment centers. Although survival data are lacking, these medications are generally well tolerated with few adverse effects.

Consultations

Most cases of squamous cell carcinoma (SCC) are easily and successfully treated by dermatologists or Mohs surgeons. However, in certain cases, a multidisciplinary approach may be needed (see "High-risk squamous cell carcinoma" in Prognosis). Such cases include the following:

A multidisciplinary approach using MMS performed in conjunction with an otolaryngologist and/or a plastic surgeon may aid in completely removing deeply invasive squamous cell carcinoma, preserving a vital structure (eg, facial nerve), and facilitating the reconstruction of a large operative defect. For example, MMS may be used in cases of squamous cell carcinoma of the scalp involving bone to establish peripheral margins to the level of the galea. MMS is then followed by resection of the deep margin, including bone, with the patient under general anesthesia, performed by a head and neck or plastic surgeon. Because the peripheral margins are established in advance, the head and neck or plastic surgeon can then focus on the deep margin and reconstruction. The patient is often spared hours of anesthesia time, lowering surgical morbidity.

Metastatic disease also requires aggressive management by a multidisciplinary team. Surgical treatment of metastatic disease may require the expertise of an otolaryngologist, a general surgeon, or a surgical oncologist. Adjuvant or palliative radiotherapy may be administered by a radiation oncologist. A medical oncologist should be consulted if systemic chemotherapy is considered for metastatic disease.

Further Outpatient Care

Low-risk tumors are usually cured with appropriate surgical therapy; however, patients who develop one squamous cell carcinoma (SCC) have a 40% risk of developing additional squamous cell carcinomas within the next 2 years. This risk is likely even greater as more time elapses. Thus, patients with a history of squamous cell carcinoma should be evaluated with a complete skin examination every 6-12 months.

Patients with high-risk tumors require skin and lymph node examinations at 3- to 6-month intervals for at least 2 years after diagnosis. In very high-risk cases, surveillance with CT scanning or MRI may be considered.

Deterrence/Prevention

General preventive measures

Prevention of squamous cell carcinoma (SCC) is best accomplished by limiting exposure to UV radiation, including both natural sunlight and artificial sources of UV light such as tanning beds. Wearing protective clothing, limiting outdoor activities (especially between 10:00 am and 4:00 pm), and applying a broad-spectrum sunscreen (ie, one that blocks UVA and UVB light) with a sun protection factor of at least 15 every day all help reduce UV exposure.

Treatment of precancerous actinic keratoses and in situ squamous cell carcinoma may prevent the future development of invasive squamous cell carcinoma. Additionally, patient education regarding skin cancer warning signs and periodic self-directed and physician-directed complete skin examinations are recommended.

Chemoprevention

Chemoprevention with systemic retinoids is effective for reducing the number of new squamous cell carcinomas in both immunocompetent and immunosuppressed patients. Most recent studies have focused on the prophylactic use of oral acitretin, which has a relatively long half-life compared with isotretinoin. Low doses are often sufficient for prophylaxis. However, treatment must be continued indefinitely because a relapse in tumor development occurs following discontinuation of oral retinoids. Furthermore, systemic retinoids have not been shown to be beneficial in treating existing squamous cell carcinoma or at reducing the risk of recurrence after treatment.[85]

The mechanisms by which retinoids protect against the development of squamous cell carcinoma have not been fully elucidated. Data suggest that retinoids induce the expression of proapoptotic and antiproliferative genes, including TP53, caspases, and P73, in keratinocytes. The increase in epidermal Langerhans cells noted in one study suggests that retinoids may also enhance cutaneous immunosurveillance.[86, 87]

Many patients are unable to tolerate the adverse effects associated with systemic retinoid therapy, although lower doses are better tolerated than higher doses. Organ transplant recipients appear to be more sensitive to the adverse effects of systemic retinoids than other patients. Adverse effects of systemic retinoids include mucocutaneous xerosis, dyslipidemia, liver function abnormalities, and teratogenicity.

Prognosis

Most squamous cell carcinomas (SCCs) are readily treated with an expectation of cure. Most large series in the literature have reported the risk of nodal or distant metastasis for primary tumors to be 2-6%.

A subset of squamous cell carcinoma carries an elevated risk of local recurrence, nodal or distant metastasis (usually to the lungs), and death. Tumors in this subset are termed high-risk squamous cell carcinoma (see below). However, prognostic models do not exist for squamous cell carcinoma. Because many of the risk factors below occur concurrently in single tumors and patients, determining which risk factors have the greatest prognostic significance is difficult. In the absence of prognostic models that take the presence of multiple risk factors into account, estimating risk for individual patients is based on very limited data and gestalt. Due to the lack of data, evidence-based decision making is often not possible. Subsequently, current management of high-risk squamous cell carcinoma varies widely.[44]

In one case series, the 3-year disease-specific survival rate for squamous cell carcinoma was estimated to be 85%. Survival rates approached 100% for lesions with no high-risk factors, but the disease-specific death rate was 30% for patients with at least 1 risk factor.[88] These estimates derived from a case series may not be reflective of the risk for squamous cell carcinoma in general and may overestimate risk. However, the data highlight that a subset of squamous cell carcinomas do poorly (see below).

When squamous cell carcinoma does metastasize, it is usually occurs within 5 years from the time of diagnosis and involves the primary (ie, first echelon) draining lymph nodes. In general, metastasis from squamous cell carcinoma of the forehead, temples, eyelids, cheeks, and ears is to the parotid nodes; metastasis from squamous cell carcinoma of the lips and perioral region is primarily to the submental and submaxillary (upper cervical) nodes.

Once nodal metastasis of cutaneous squamous cell carcinoma has occurred, the overall 5-year survival rate has historically been in the range of 25-35%. Prognosis is extremely poor for patients with a compromised immune system, with metastasis to multiple lymph nodes, or with cervical lymph nodes greater than 3 cm in diameter. Nevertheless, data published in 2005 show that the combined use of surgery and adjuvant radiotherapy for patients with nodal metastasis increased the 5-year disease-specific survival rate to 73%.[17] Metastasis to distant organs remains incurable. Thus, close surveillance and early detection of nodal metastasis can be life saving and is of paramount importance.

High-risk squamous cell carcinoma

A subset of squamous cell carcinoma is considered high risk because it has been associated with higher rates of recurrence, metastasis, and death in case series data. Squamous cell carcinoma can be characterized as high-risk by virtue of tumor-related factors (intrinsic factors), patient-related factors (extrinsic factors), or a combination of both.

Tumor-related factors in high-risk squamous cell carcinoma[78]

Tumor-related factors are (1) tumor location (ie, lips, ears, anogenital, within a scar or chronic wound), (2) tumor size greater than 2 cm (or 1.5 cm on ear or lip), (3), invasion to subcutaneous fat (or deeper), (4) poorly differentiated tumor cells, (5) recurrent tumor, and (6) perineural involvement (except perhaps for tumors with small-caliber nerve invasion and no other risk factors.[48]

Additionally, a prospective study of 210 patients with a diverse range of squamous cell carcinomas showed tumor-related factors were associated with adverse disease-specific survival using univariate analyses.[88] Specifically, these factors were (1) local recurrence at presentation (P = .05), (2) invasion beyond subcutaneous tissue (P = .009), (3) depth in general (P = .05), (4) perineural invasion (P = .002), and (5) size greater than or equal to 4 cm (P = .0003).

Detailed information on tumor-related factors is as follows:

Patient-related factors in high-risk squamous cell carcinoma

General patient-related factors are (1) organ transplant recipient, (2) hematologic malignancy (eg, chronic lymphocytic leukemia), (3) long-term immunosuppressive therapy, and (4) HIV infection or AIDS.

Detailed information on patient-related factors is as follows:

Other reported conditions associated with aggressive squamous cell carcinoma

The risk of squamous cell carcinoma in patients with bullous disease is markedly elevated. The risk of death is particularly high in those with epidermolysis bullosa, with an 80% mortality rate 5 years after diagnosis of first primary squamous cell carcinoma.

Other reported conditions include arsenic exposure[95] and psoralen plus UVA (PUVA) light exposure.

References

  1. Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol. Mar 1992;26(3 Pt 2):467-84.[View Abstract]
  2. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. Jun 1992;26(6):976-90.[View Abstract]
  3. Brantsch KD, Meisner C, Schonfisch B, et al. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study. Lancet Oncol. Aug 2008;9(8):713-20.[View Abstract]
  4. Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. Adv Exp Med Biol. 2008;624:89-103.[View Abstract]
  5. Masini C, Fuchs PG, Gabrielli F, et al. Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals. Arch Dermatol. Jul 2003;139(7):890-4.[View Abstract]
  6. Wong SS, Tan KC, Goh CL. Cutaneous manifestations of chronic arsenicism: review of seventeen cases. J Am Acad Dermatol. Feb 1998;38(2 Pt 1):179-85.[View Abstract]
  7. Herman S, Rogers HD, Ratner D. Immunosuppression and squamous cell carcinoma: a focus on solid organ transplant recipients. Skinmed. Sep-Oct 2007;6(5):234-8.[View Abstract]
  8. Mehrany K, Weenig RH, Pittelkow MR, Roenigk RK, Otley CC. High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia. Dermatol Surg. Jan 2005;31(1):38-42; discussion 42.[View Abstract]
  9. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol. Jun 2002;138(6):758-63.[View Abstract]
  10. Mallipeddi R. Epidermolysis bullosa and cancer. Clin Exp Dermatol. Nov 2002;27(8):616-23.[View Abstract]
  11. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636.[View Abstract]
  12. Newman MD, Weinberg JM. Topical therapy in the treatment of actinic keratosis and basal cell carcinoma. Cutis. Apr 2007;79(4 Suppl):18-28.[View Abstract]
  13. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol. May 1994;30(5 Pt 1):774-8.[View Abstract]
  14. Gray DT, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol. Jun 1997;133(6):735-40.[View Abstract]
  15. Hampton T. Skin cancer's ranks rise: immunosuppression to blame. JAMA. Sep 28 2005;294(12):1476-80.[View Abstract]
  16. Buettner PG, Raasch BA. Incidence rates of skin cancer in Townsville, Australia. Int J Cancer. Nov 23 1998;78(5):587-93.[View Abstract]
  17. Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. May 2005;115(5):870-5.[View Abstract]
  18. McCall CO, Chen SC. Squamous cell carcinoma of the legs in African Americans. J Am Acad Dermatol. Oct 2002;47(4):524-9.[View Abstract]
  19. Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys. Mar 15 2001;49(4):1061-9.[View Abstract]
  20. Kowal-Vern A, Criswell BK. Burn scar neoplasms: a literature review and statistical analysis. Burns. Jun 2005;31(4):403-13.[View Abstract]
  21. Turegun M, Nisanci M, Guler M. Burn scar carcinoma with longer lag period arising in previously grafted area. Burns. Sep 1997;23(6):496-7.[View Abstract]
  22. Fleming MD, Hunt JL, Purdue GF, Sandstad J. Marjolin's ulcer: a review and reevaluation of a difficult problem. J Burn Care Rehabil. Sep-Oct 1990;11(5):460-9.[View Abstract]
  23. Moller R, Reymann F, Hou-Jensen K. Metastases in dermatological patients with squamous cell carcinoma. Arch Dermatol. Jun 1979;115(6):703-5.[View Abstract]
  24. Novick M, Gard DA, Hardy SB, Spira M. Burn scar carcinoma: a review and analysis of 46 cases. J Trauma. Oct 1977;17(10):809-17.[View Abstract]
  25. Moy RL, Eliezri YD, Nuovo GJ, Zitelli JA, Bennett RG, Silverstein S. Human papillomavirus type 16 DNA in periungual squamous cell carcinomas. JAMA. May 12 1989;261(18):2669-73.[View Abstract]
  26. de Gruijl FR, Rebel H. Early events in UV carcinogenesis--DNA damage, target cells and mutant p53 foci. Photochem Photobiol. Mar-Apr 2008;84(2):382-7.[View Abstract]
  27. Katiyar SK. UV-induced immune suppression and photocarcinogenesis: chemoprevention by dietary botanical agents. Cancer Lett. 2007;255:1-11.[View Abstract]
  28. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. Dec 22-29 1994;372(6508):773-6.[View Abstract]
  29. Brown VL, Harwood CA, Crook T, Cronin JG, Kelsell DP, Proby CM. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol. May 2004;122(5):1284-92.[View Abstract]
  30. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. Dec 22-29 1994;372(6508):773-6.[View Abstract]
  31. Perry PK, Silverberg NB. Cutaneous malignancy in albinism. Cutis. May 2001;67(5):427-30.[View Abstract]
  32. Karagas MR, Nelson HH, Zens MS, et al. Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology. Nov 2007;18(6):776-84.[View Abstract]
  33. Zghal M, El-Fekih N, Fazaa B, et al. [Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 49 Tunisian cases]. Tunis Med. Dec 2005;83(12):760-3.[View Abstract]
  34. Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol. Jul 2002;47(1):1-17; quiz 18-20.[View Abstract]
  35. Black AP, Bailey A, Jones L, Turner RJ, Hollowood K, Ogg GS. p53-specific CD8+ T-cell responses in individuals with cutaneous squamous cell carcinoma. Br J Dermatol. Nov 2005;153(5):987-91.[View Abstract]
  36. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol. Apr 2009;10(4):321-2.[View Abstract]
  37. Alam M, Caldwell JB, Eliezri YD. Human papillomavirus-associated digital squamous cell carcinoma: literature review and report of 21 new cases. J Am Acad Dermatol. Mar 2003;48(3):385-93.[View Abstract]
  38. Della Torre G, Donghi R, Longoni A, et al. HPV DNA in intraepithelial neoplasia and carcinoma of the vulva and penis. Diagn Mol Pathol. Mar 1992;1(1):25-30.[View Abstract]
  39. Stockfleth E, Nindl I, Sterry W, Ulrich C, Schmook T, Meyer T. Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg. Apr 2004;30(4 Pt 2):604-9.[View Abstract]
  40. Fine JD, Johnson LB, Weiner M, Li KP, Suchindran C. Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol. Feb 2009;60(2):203-11.[View Abstract]
  41. Reed WB, College J Jr, Francis MJ, et al. Epidermolysis bullosa dystrophica with epidermal neoplasms. Arch Dermatol. Dec 1974;110(6):894-902.[View Abstract]
  42. Mallipeddi R, Keane FM, McGrath JA, Mayou BJ, Eady RA. Increased risk of squamous cell carcinoma in junctional epidermolysis bullosa. J Eur Acad Dermatol Venereol. Sep 2004;18(5):521-6.[View Abstract]
  43. Arbiser JL, Fan CY, Su X, et al. Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol. Oct 2004;123(4):788-90.[View Abstract]
  44. Jambusaria-Pahlajani A, Hess S, Berg D, Schmults CD. Equipoise exists in the peri-operative management of cutaneous squamous cell carcinoma with perineural invasion: A survey study of American College of Mohs Surgery surgeons. Manuscript under review.
  45. Williams LS, Mancuso AA, Mendenhall WM. Perineural spread of cutaneous squamous and basal cell carcinoma: CT and MR detection and its impact on patient management and prognosis. Int J Radiat Oncol Biol Phys. Mar 15 2001;49(4):1061-9.[View Abstract]
  46. Land R, Herod J, Moskovic E, et al. Routine computerized tomography scanning, groin ultrasound with or without fine needle aspiration cytology in the surgical management of primary squamous cell carcinoma of the vulva. Int J Gynecol Cancer. Jan-Feb 2006;16(1):312-7.[View Abstract]
  47. Cho SB, Chung WG, Yun M, Lee JD, Lee MG, Chung KY. Fluorodeoxyglucose positron emission tomography in cutaneous squamous cell carcinoma: retrospective analysis of 12 patients. Dermatol Surg. Apr 2005;31(4):442-6; discussion 446-7.[View Abstract]
  48. Ross AS, Schmults CD. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature. Dermatol Surg. Nov 2006;32(11):1309-21.[View Abstract]
  49. Cutaneous Squamous Cell Carcinoma and Other Cutaneous Carcinomas. In: Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009:301-09.
  50. O'Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS, Jackson MA. Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck. May 2002;24(5):417-22.[View Abstract]
  51. Palme CE, O'Brien CJ, Veness MJ, McNeil EB, Bron LP, Morgan GJ. Extent of parotid disease influences outcome in patients with metastatic cutaneous squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. Jul 2003;129(7):750-3.[View Abstract]
  52. Andruchow JL, Veness MJ, Morgan GJ, et al. Implications for clinical staging of metastatic cutaneous squamous carcinoma of the head and neck based on a multicenter study of treatment outcomes. Cancer. Mar 1 2006;106(5):1078-83.[View Abstract]
  53. Audet N, Palme CE, Gullane PJ, et al. Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck. Aug 2004;26(8):727-32.[View Abstract]
  54. Ch'ng S, Maitra A, Allison RS, et al. Parotid and cervical nodal status predict prognosis for patients with head and neck metastatic cutaneous squamous cell carcinoma. J Surg Oncol. Aug 1 2008;98(2):101-5.[View Abstract]
  55. Forest VI, Clark JJ, Veness MJ, Milross C. N1S3: a revised staging system for head and neck cutaneous squamous cell carcinoma with lymph node metastases: results of 2 Australian Cancer Centers. Cancer. Mar 1 2010;116(5):1298-304.[View Abstract]
  56. Bargman H, Hochman J. Topical treatment of Bowen's disease with 5-Fluorouracil. J Cutan Med Surg. Mar-Apr 2003;7(2):101-5.[View Abstract]
  57. Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. Mar 2001;44(3):462-70.[View Abstract]
  58. Smith KJ, Hamza S, Skelton H. Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern. Clin Exp Dermatol. Sep 2004;29(5):505-12.[View Abstract]
  59. Perrett CM, McGregor JM, Warwick J, et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. Feb 2007;156(2):320-8.[View Abstract]
  60. Willey A, Mehta S, Lee PK. Reduction in the Incidence of Squamous Cell Carcinoma in Solid Organ Transplant Recipients Treated with Cyclic Photodynamic Therapy. Dermatol Surg. Nov 4 2009;[View Abstract]
  61. Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg. Feb 2004;30(2 Pt 2):264-71.[View Abstract]
  62. Veness M, Richards S. Role of modern radiotherapy in treating skin cancer. Australas J Dermatol. Aug 2003;44(3):159-66; quiz 167-8.[View Abstract]
  63. Ross AS, Whalen FM, Elenitsas R, Xu X, Troxel AB, Schmults CD. Diameter of involved nerves predicts outcomes in cutaneous squamous cell carcinoma with perineural invasion: an investigator-blinded retrospective cohort study. Derm Surg Dec 2009. Dec 2009;35(12):1859-66.[View Abstract]
  64. Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. Apr 2009;35(4):574-85.[View Abstract]
  65. Wollina U, Hansel G, Koch A, Kostler E. Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin. J Cancer Res Clin Oncol. May 2005;131(5):300-4.[View Abstract]
  66. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. Jul 2007;143(7):889-92.[View Abstract]
  67. Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. Aug 2007;18(7):827-9.[View Abstract]
  68. Arnold AW, Bruckner-Tuderman L, Zuger C, Itin PH. Cetuximab therapy of metastasizing cutaneous squamous cell carcinoma in a patient with severe recessive dystrophic epidermolysis bullosa. Dermatology. 2009;219(1):80-3.[View Abstract]
  69. Hitt R, Jimeno A, Rodriguez-Pinilla M,et al. Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer. Dec 13 2004;91(12):2005-11.[View Abstract]
  70. Bentzen JD, Hansen HS. Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region. Head Neck. Jan 2007;29(1):47-51.[View Abstract]
  71. Kim JG, Sohn SK, Kim DH, et al. Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer. Nov 14 2005;93(10):1117-21.[View Abstract]
  72. Otley CC, Cherikh WS, Salasche SJ, McBride MA, Christenson LJ, Kauffman HM. Skin cancer in organ transplant recipients: effect of pretransplant end-organ disease. J Am Acad Dermatol. Nov 2005;53(5):783-90.[View Abstract]
  73. Abou Ayache R, Thierry A, Bridoux F, et al. Long-term maintenance of calcineurin inhibitor monotherapy reduces the risk for squamous cell carcinomas after kidney transplantation compared with bi- or tritherapy. Transplant Proc. Oct 2007;39(8):2592-4.[View Abstract]
  74. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. Jan 27 2009;87(2):233-42.[View Abstract]
  75. Rival-Tringali AL, Euvrard S, Decullier E, Claudy A, Faure M, Kanitakis J. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas. Anticancer Res. Jun 2009;29(6):1927-32.[View Abstract]
  76. Kuflik EG, Gage AA. The five-year cure rate achieved by cryosurgery for skin cancer. J Am Acad Dermatol. Jun 1991;24(6 Pt 1):1002-4.[View Abstract]
  77. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol. Aug 1992;27(2 Pt 1):241-8.[View Abstract]
  78. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. Jun 1992;26(6):976-90.[View Abstract]
  79. Seidler AM, Bramlette TB, Washington CV, Szeto H, Chen SC. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: an analysis of cost-effectiveness. Dermatol Surg. Nov 2009;35(11):1776-87.[View Abstract]
  80. Rogers HW, Coldiron BM. A relative value unit-based cost comparison of treatment modalities for nonmelanoma skin cancer: effect of the loss of the Mohs multiple surgery reduction exemption. J Am Acad Dermatol. Jul 2009;61(1):96-103.[View Abstract]
  81. Holmkvist KA, Roenigk RK. Squamous cell carcinoma of the lip treated with Mohs micrographic surgery: outcome at 5 years. J Am Acad Dermatol. Jun 1998;38(6 Pt 1):960-6.[View Abstract]
  82. Robins P, Dzubow LM, Rigel DS. Squamous-cell carcinoma treated by Mohs' surgery: an experience with 414 cases in a period of 15 years. J Dermatol Surg Oncol. Oct 1981;7(10):800-1.[View Abstract]
  83. Harwood CA, Leedham-Green M, Leigh IM, Proby CM. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol. Apr 2005;141(4):456-64.[View Abstract]
  84. Tan PY, Ek E, Su S, Giorlando F, Dieu T. Incomplete excision of squamous cell carcinoma of the skin: a prospective observational study. Plast Reconstr Surg. Sep 15 2007;120(4):910-6.[View Abstract]
  85. Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol. Mar 2005;152(3):518-23.[View Abstract]
  86. Mrass P, Rendl M, Mildner M, et al. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res. Sep 15 2004;64(18):6542-8.[View Abstract]
  87. Papoutsaki M, Lanza M, Marinari B, et al. The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene. J Invest Dermatol. Dec 2004;123(6):1162-8.[View Abstract]
  88. Clayman GL, Lee JJ, Holsinger FC, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. Feb 1 2005;23(4):759-65.[View Abstract]
  89. Jensen P, Hansen S, Moller B, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. Feb 1999;40(2 Pt 1):177-86.[View Abstract]
  90. Euvrard S, Kanitakis J, Decullier E, et al. Subsequent skin cancers in kidney and heart transplant recipients after the first squamous cell carcinoma. Transplantation. Apr 27 2006;81(8):1093-100.[View Abstract]
  91. Veness MJ, Quinn DI, Ong CS, et al. Aggressive cutaneous malignancies following cardiothoracic transplantation: the Australian experience. Cancer. Apr 15 1999;85(8):1758-64.[View Abstract]
  92. Mehrany K, Weenig RH, Pittelkow MR, Roenigk RK, Otley CC. High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia. Dermatol Surg. Jan 2005;31(1):38-42; discussion 42.[View Abstract]
  93. Frierson HF Jr, Deutsch BD, Levine PA. Clinicopathologic features of cutaneous squamous cell carcinomas of the head and neck in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol. Dec 1988;19(12):1397-402.[View Abstract]
  94. Lobo DV, Chu P, Grekin RC, Berger TG. Nonmelanoma skin cancers and infection with the human immunodeficiency virus. Arch Dermatol. May 1992;128(5):623-7.[View Abstract]
  95. Straif K, Benbrahim-Tallaa L, Baan R, et al. A review of human carcinogens--part C: metals, arsenic, dusts, and fibres. Lancet Oncol. May 2009;10(5):453-4.[View Abstract]

Sun-induced squamous cell carcinoma on the face with overlying hyperkeratosis, a common feature.

Squamous cell carcinoma of the penis. Courtesy of Hon Pak, MD.

Sun-induced squamous cell carcinoma on the face with superficial erosion.

Squamous cell carcinoma. Courtesy of Hon Pak, MD.

TumorHistologic CharacteristicsClinical Characteristics
KeratoacanthomaKeratin-filled crater

Well-differentiated (mild atypia)

Neutrophil microabscesses

Eosinophils in dermal infiltrate

Elastic tissue trapping

Lack of acantholysis

Solitary nodule

Central craterlike depression

Rapid growth

May spontaneously involute

Spindle cell SCCAtypical spindle cells

Foci of squamous differentiation

May resemble other spindle cell tumors (eg, atypical fibroxanthoma)

Resembles typical SCC

May be clinically aggressive

Acantholytic (adenoid) SCCGlandlike differentiation

Acantholysis

May resemble adenocarcinoma or sweat gland carcinoma

Arises on sun-damaged skin

Elderly patients

Resembles typical SCC

Clinically aggressive

Verrucous carcinomaWell-differentiated (glassy atypia)

Surface resembles verruca

Bulbous downward proliferation

"Bulldozing" invasion

Oral, genital, or plantar foot

Indolent growth

Locally destructive

Rarely metastasizes

Sarcomatoid SCCPoorly differentiated cells resembling sarcomaClinical appearance may be that of typical SCC or may have more nodular appearance with less surface change

Elevated risk of local recurrence and metastasis